Progress and regression within primary Sjögren's syndrome
- PMID: 16467033
- DOI: 10.1080/03009740500537945
Progress and regression within primary Sjögren's syndrome
Abstract
The purpose of this review is to give a modern view and an update of important areas in primary Sjögren's syndrome (SS), which may be the most common of the autoimmune systemic rheumatic diseases. Interest in aspects of primary SS including clinical manifestations, pathogenesis, aetiology, treatment, prognosis, etc has increased during the past three decades, the volume of scientific papers and the number of theses being the indicators. However, only a fraction of the money that is used for research into rheumatoid arthritis (RA) is used for SS, and the statement that SS is under-diagnosed, under-treated and under-researched will still be valid for several years to come. The topics that are focused on in this review are: (a) clinical areas with subsections on signs and symptoms, terminology, predictors for development of non-Hodgkin malignant lymphoma (NHML) and prognosis, (b) treatment, (c) the Danger model (aetiopathogenesis) and (d) pathology, including immunoglobulin G4 (IgG4)-positive cells.
Similar articles
-
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.Arthritis Rheum. 2005 Sep;52(9):2740-50. doi: 10.1002/art.21260. Arthritis Rheum. 2005. PMID: 16142737 Clinical Trial.
-
Pulmonary manifestations of primary Sjögren's syndrome.Indian J Chest Dis Allied Sci. 2009 Apr-Jun;51(2):93-101. Indian J Chest Dis Allied Sci. 2009. PMID: 19445445 Review.
-
The therapy of Sjogren's syndrome: a review.Clin Ter. 2007 Sep-Oct;158(5):453-6. Clin Ter. 2007. PMID: 18062353 Review.
-
Rituximab therapy in primary Sjögren's syndrome.Ann N Y Acad Sci. 2009 Sep;1173:701-5. doi: 10.1111/j.1749-6632.2009.04639.x. Ann N Y Acad Sci. 2009. PMID: 19758218
-
Antimalarials in Sjögren's syndrome--the Greek experience.Lupus. 1996 Jun;5 Suppl 1:S28-30. Lupus. 1996. PMID: 8803907 Review.
Cited by
-
Transcriptome analysis of the interferon-signature defining the autoimmune process of Sjögren's syndrome.Scand J Immunol. 2012 Sep;76(3):237-45. doi: 10.1111/j.1365-3083.2012.02749.x. Scand J Immunol. 2012. PMID: 22703193 Free PMC article.
-
The Interferon-Signature of Sjögren's Syndrome: How Unique Biomarkers Can Identify Underlying Inflammatory and Immunopathological Mechanisms of Specific Diseases.Front Immunol. 2013 Jul 5;4:142. doi: 10.3389/fimmu.2013.00142. eCollection 2013. Front Immunol. 2013. PMID: 23847613 Free PMC article.
-
Primary Sjogrens syndrome is associated with impaired autonomic response to orthostasis and sympathetic failure.QJM. 2012 Dec;105(12):1191-9. doi: 10.1093/qjmed/hcs172. Epub 2012 Sep 13. QJM. 2012. PMID: 22976617 Free PMC article.
-
[Is bioptic assurance reasonable in patients with Sjögren's syndrome? From focus score to diagnosing vasculitides].Z Rheumatol. 2010 Feb;69(1):11-8. doi: 10.1007/s00393-009-0514-7. Z Rheumatol. 2010. PMID: 19997922 Review. German.
-
Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3.J Immunol. 2007 Aug 15;179(4):2318-29. doi: 10.4049/jimmunol.179.4.2318. J Immunol. 2007. PMID: 17675493 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous